Articles tagged with Osteoporosis
The absence of platelet-activating factor receptor in mice with induced menopause leads to improved bone mineral density and volume. Osteoclasts are responsible for PAF's mechanism of action, and inhibiting PAF receptor function reduces bone resorption.
Researchers at CAMOS found a significant 'osteoporosis care gap,' with many cases going undetected in older adults. The study also revealed that even diagnosis can lead to a decline in quality of life due to fear of fractures.
Dr. Charles Pak, a renowned researcher, has been recognized with an international award for his groundbreaking work on kidney-stone disease treatment methodologies. He has developed several drugs used worldwide and diagnostic methods for measuring risk factors, improving patient outcomes.
Research finds that mitochondrial function decline is a critical mechanism driving aging, leading to premature aging in mice. The study highlights the potential for protecting mitochondrial DNA from damage to slow down aging and treat related pathological changes.
Researchers analyzed data from 149,524 postmenopausal women to identify predictors of bone fractures. Women with low T scores or previous fractures were found to be at increased risk, highlighting the need for targeted interventions.
A recent study found that height loss of between 2-3 inches increases the risk of hip osteoporosis by nearly fourfold. Researchers suggest a simple evaluation of height can help physicians decide whether patients should undergo a bone density scan to check for osteoporosis.
A statistical model predicts rapid increase in spinal fractures over time if left untreated, highlighting the importance of intervention before first fracture occurs. The study emphasizes the need for therapy that reduces risk of first fracture within one year to substantially reduce future fracture risk.
A randomized trial compared the effects of raloxifene and CEE on bone mineral density in postmenopausal women with prior hysterectomy. The study found that CEE increased bone density by 4.6%, while raloxifene stabilized bone density, and both treatments had varying impacts on cholesterol levels.
A study by University of Alberta researchers found that 22 patients had vertebral fractures, with 45% going undiagnosed. Vertebral fractures often indicate osteoporosis, a common disease in the elderly that can be easily treated with drugs.
A Baylor College of Medicine study reveals that the hormone amylin inhibits bone loss and resorption. Mice without amylin have less bone mass due to increased bone destruction, suggesting a potential therapeutic avenue for preventing osteoporosis in Type 1 diabetes patients.
A study published in Science has identified the Alox15 gene as a potential human therapeutic target for osteoporosis risk. The gene's over-activity leads to reduced bone density and increased risk of osteoporosis, but inhibitors of the gene's enzyme can improve bone mass and strength.
A study identified variants of the BMP2 gene as genetic risk factors for osteoporosis, approximately tripling the likelihood of developing the disease. The findings were replicated in an independent cohort, suggesting a strong association between the gene's variants and increased risk of osteoporotic fractures.
Two studies found that combining parathyroid hormone (PTH) and alendronate increases bone mineral density (BMD) at least as well as or better than single drug treatment. Further studies are needed to determine the optimal effects of these drugs, particularly through sequential or cyclic therapy.
A new study found that Actonel maintained the size of calcium-based mineral crystals and the integrity of collagen structure over five years, preserving bone quality. This is significant because osteoporosis therapies should aim to reduce fracture risk, not just treat symptoms.
A recent study by Massachusetts General Hospital found that combining osteoporosis treatments does not produce better results. Injections of PTH, a treatment initially developed through MGH research, increase bone formation and were superior to alendronate alone in improving bone density.
A new study found that combining osteoporosis medications, parathyroid hormone and bisphosphonates, does not provide additional benefits to patients. The trial of 238 postmenopausal women showed no significant improvement in bone density or anabolic effects when both drugs were used together.
A study conducted at the University of Melbourne found that smoking is significantly linked to osteoporosis in women, particularly after menopause. Continuing high exposure to tobacco and greater sensitivity to smoking-induced bone loss are possible explanations for this link.
Researchers at Purdue University have developed a new tool using dual energy X-ray absorptiometry (DEXA) to accurately determine bone mineral density in hens. The study found that more calcium resulted in greater bone mineral density and stronger bones, leading to potential improvements in egg production.
Researchers highlight the growing concern of male osteoporosis, emphasizing genetic predispositions and secondary risk factors such as alcohol consumption and malnutrition. Dr. Rosen recommends early bone density testing for men over 55 with unexplained height loss or fracture history to identify potential treatment options.
A study analyzing data from pivotal trials of Actonel revealed that bone mineral density explains only a small portion of nonvertebral fracture risk reduction. The analysis found that BMD increases accounted for just 12.2% of the fracture risk reduction at lumbar spine, and 5.5% at femoral neck.
A 7-year study shows Actonel significantly reduces vertebral fracture incidence, with annualized rates of 4.7%, 5.2%, and 3.8% for the treatment group, respectively. Adverse events were similar to those in patients taking placebo during the first 5 years.
A new study published in JAMA found that a combination therapy of hormone replacement and alendronate was well-tolerated by elderly women with low bone mass. After three years, participants taking the combination therapy showed significantly greater increases in bone mass compared to those taking individual therapies.
A recent study evaluated the medical costs of osteoporosis therapies and found that patients taking weekly Fosamax had lower GI-related medical costs compared to those taking daily or weekly doses. The analysis, conducted with a large medical claims database, also revealed that treating patients with a weekly dose of Fosamax versus a d...
A study found that mice genetically engineered to lack a molecule called Stem Cell Antigen-1 (Sca-1) experienced normal bone development but exhibited decreased bone mass and brittle bones as they aged. The researchers believe that defective maintenance of stem cells may contribute to age-related osteoporosis in humans.
A University of Pittsburgh study found significant imbalance in bone turnover among post-operative patients undergoing stomach-reduction surgery, resulting in up to an 8% drop in bone density. The researchers suggest that major weight loss requires ongoing calcium and vitamin supplementation for bone health.
Actonel significantly reduced fracture risk in high-risk postmenopausal women, with a 62% reduction seen at one year. The medication was found to be effective in reducing spinal fractures in patients over 70 years old and those with low hip BMD.
Researchers at the University of Pittsburgh discovered that PTHrP significantly increases bone mineral density in postmenopausal women with osteoporosis, with a 4.7% increase observed in just three months. The study's findings are promising and take the identification of an effective short-term anabolic agent one step further.
A study projects that increasing BMD testing for women with osteoporosis or osteopenia would reduce fractures by 6,683 over three years and result in net Medicare savings of $15.5 million. This could lead to increased patient benefits while reducing costs.
Researchers at the University of Wisconsin-Madison have discovered a potent Vitamin D analog, known as 2MD, which significantly increases bone density in rats with osteoporosis. The compound has shown no apparent toxicity and may become an alternative to hormone replacement therapy.
The USPSTF recommends that physicians routinely screen women over 65 for osteoporosis, a thinning of the bones that can lead to bone fracture. Women at higher than average risk should begin screening at age 60. Early nephrologist care is associated with better outcomes for kidney disease patients, particularly those with African-Americ...
The US Preventive Services Task Force recommends routine osteoporosis screening to reduce fracture risk in women with low bone density. The optimal frequency of testing is unclear, but intervals of two to five years are most consistent with current understanding.
The ACP-ASIM published 'Osteoporosis' guide provides the latest scientific evidence on osteoporosis and essential information on its origins and progress. It addresses every facet of osteoporosis, a common disease that can be identified through non-invasive tests and treated with new effective drugs to reduce fractures.
Researchers analyzed historical placebo control data with Actonel treatment for osteoporosis, revealing a significant reduction in new vertebral fractures. The study found that once-week treatment with Actonel reduced the risk of new vertebral fractures by 77% at one year.
A new analysis shows that Actonel reduced the risk of nonvertebral osteoporotic fractures by 74 percent within one year in postmenopausal women with osteoporosis. The effect was observed as early as six months, and the study included 1172 patients who received either placebo or Actonel 5 mg daily.
A study found that Actonel significantly slows deterioration in trabecular bone microarchitecture after just one year, while a placebo had no such effect. This suggests that protection of bone microarchitecture may play an important role in bone health.
A population-based study found nearly half of women screened for osteoporosis were undiagnosed, while half with the condition didn't receive treatment. Factors influencing therapy included lower bone mineral density and higher education.
A new analysis reveals that early intervention with Actonel significantly reduces the risk of first vertebral fractures in postmenopausal women. The study found a 75% decrease in fracture risk among women treated with Actonel, compared to those on placebo.
A new study by UCSF researchers reveals that osteoporosis has significant economic costs for Californians, with Medicare paying for most hospital care and nursing home care being the largest expense. Early detection and prevention are critical to reducing these costs, which include indirect losses due to premature death.
Women with irregular periods are at increased risk of developing osteoporosis later in life, according to a recent study. The research found that nearly all women with premature ovarian failure reported changes in their menstrual cycle, highlighting the importance of early evaluation and treatment.
A study by UCSF found that consuming excessive salt increases calcium loss, while a potassium supplement helps maintain bone density. Potassium-rich foods like bananas and spinach can be beneficial for preventing osteoporosis in postmenopausal women.
The FDA has approved Actonel 35 mg once-a-week for the treatment and prevention of postmenopausal osteoporosis, showing a significant increase in lumbar spine bone mineral density at 12 months. The study found that once-a-week dosing is therapeutically equivalent to daily dosing.
A Yale research team identified a genetic mutation in the Wnt signaling pathway that leads to high bone density, a trait seen in one in a million people with no symptoms. The findings suggest a new route for developing medications to increase bone density and prevent osteoporosis without clinical side effects.
A study published in the Journal of Clinical Endocrinology and Metabolism has linked six genetic base substitutions to absorptive hypercalciuria, a condition that causes about 45% of all kidney stones. The presence of these base substitutions increases the risk of bone loss and osteoporosis.
Researchers found that raloxifene reduced the risk of cardiovascular events by 40% in postmenopausal women with osteoporosis who were also at high risk for cardiovascular disease. A subset of 1,035 women showed a significant reduction in cardiovascular events compared to placebo.
A new study finds that raloxifene, an osteoporosis medication, reduces breast cancer risk by 76% in postmenopausal women with high estrogen levels. Women with low estrogen levels receive no reduction in risk.
The largest US study on osteoporosis risk factors found that almost half of women over 50 are at risk for the bone disease. The study, led by Dr. Ethel Siris, highlights the need for more women to get tested and treated for osteoporosis, as it can lead to debilitating fractures.
A genetic 'thermostat' called LRP5 regulates bone mass during growth and may contribute to normal variation in bone strength. The discovery could lead to new treatments for rare genetic disorders and potentially increase bone density in the general population.
A new study found that Actonel 35mg taken once a week was equally effective to 5mg daily in improving bone density in postmenopausal women. The treatment also showed a comparable adverse event profile. This alternative dosing regimen may be beneficial for some patients and physicians.
A two-year study of postmenopausal monkeys found tibolone improved bone mineral density while reducing cardiovascular risks compared to estrogen-based treatments. However, it may offer advantages in breast and uterine safety over other options.
A 42-month study published in Archives of Internal Medicine found that sustained-release sodium fluoride safely reduces the risk for vertebral fractures and increases spinal bone mass in older women with osteoporosis. The treatment combination also reduced bone resorption when adequate calcium and vitamin D were provided.
A study presented at the American College of Gastroenterology meeting found that Actonel 5mg daily significantly reduced vertebral fracture risk by 70% in patients on chronic glucocorticoid therapy. Patients who received calcium supplementation and vitamin D also experienced significant reductions in bone loss.
A study of 96 elderly women found that high caffeine intake (over 300mg/day) accelerates bone loss, especially in those with the tt VDR genotype. Moderate caffeine consumption is not linked to increased bone loss, and doctors recommend adequate calcium and moderate caffeine for their patients.
New findings show that Actonel therapy can reduce clinical vertebral fractures in postmenopausal women as early as six months. The data suggests that treatment with Actonel can stop the fracture cascade and improve bone health.
Campers receive controlled dietary intake of calcium, allowing researchers to track bone density changes and determine optimal levels. The goal is to establish guidelines that will help slow bone density decline after middle age.
A strong association has been found between depression and osteoporosis, with depressed individuals experiencing lower bone mineral density. Research suggests that depression may contribute to hormonal abnormalities leading to bone loss and changes in body composition.
A retrospective analysis found that Risedronate reduced nonvertebral fracture risk by 69% at six months, compared to a 54% reduction in risk for patients taking Alendronate. This study suggests that Risedronate is an effective treatment option for osteoporosis prevention and treatment.
A low dose of estrogen was as effective as a higher dose in reducing bone turnover and preventing osteoporosis in older women. The study found that women taking 0.25 mg estradiol had no more side effects than those taking a placebo, improving bone health with fewer risks.
A study found that only 18.5% of patients with fragility fractures received a proper osteoporosis diagnosis, and even fewer were treated accordingly. This gap in care represents a significant lost opportunity to build bone mass and reduce fracture risk among Canada's aging population.
Researchers at the University of Alberta have developed a novel drug delivery system that targets bones directly, potentially treating osteoporosis more effectively. The system uses growth factors to stimulate bone cells and retains the drug in the targeted area, reducing side effects.
A large clinical trial is underway at UCSF to study a combination drug therapy for osteoporosis, using recombinant human parathyroid hormone (1-84) and alendronate. The trial aims to combine agents that speed up bone formation and resorption with those that slow down resorption, resulting in a net gain of bone strength.